Ironwood Pharmaceuticals, Inc. (IRWD) managed to eke out gains of 4.59% in intraday trade. The share price increased by 0.66 points to $15.04. Till last observation, the net money flow was recorded at a negative $(-1.45) million. The total inflow of $1.63 million in upticks was completely overshadowed by an outflow of $3.08 million in downticks, giving the up/down ratio a value of 0.53. The shares have seen a change of 7.66% in the past week.A block trade occurred in the company shares in which the composite value of the upticks was $0.18 million and the composite value in downticks was $2.05 million. The resultant up/down ratio for the block exchange was 0.09. The block trade had a negative money flow of $(-1.87) million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Ironwood Pharmaceuticals, Inc. appreciated by 4.8% during the last five trading days but lost 1.44% on a 4-week basis. Ironwood Pharmaceuticals, Inc. is up 18.01% in the last 3-month period. Year-to-Date the stock performance stands at -1.44%. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rose 4.8% or 0.69 points on Wednesday and made its way into the gainers of the day. After trading began at $14.38 the stock was seen hitting $15.11 as a peak level and $14.37 as the lowest level. The stock ended up at $15.07. The daily volume was measured at 1,744,978 shares. The 52-week high of the share price is $16.89 and the 52-week low is $7.35. The company has a market cap of $2,204 million.
Company has reported several Insider transactions to the SEC, on Jan 13, 2017, Peter M Hecht (Chief Executive Officer) sold 65,987 shares at 15.67 per share price.On Dec 7, 2016, Lawrence S Olanoff (director) sold 3,200 shares at 15.68 per share price.On Nov 15, 2016, Halley E Gilbert (Chief Legal Officer) sold 14,000 shares at 16.75 per share price.
Ironwood Pharmaceuticals Last issued its quarterly earnings results on Nov 3, 2016. The company reported $-0.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.05. Analyst had a consensus of $-0.23. The company had revenue of $66.00 million for the quarter, compared to analysts expectations of $60.01 million. The companys revenue was up 66.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.25 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Reiterated by Mizuho on Nov 4, 2016 to Buy, Raises Price Target to $ 20 from a previous price target of $19 .
Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines. The Companys first in class compound, Linaclotide, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation and chronic constipation. The Company also focuses on one Phase 1 pain drug candidate and multiple preclinical programs, as well as on building a specialty biochemicals business based on a proprietary strain-development platform. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is headquartered in Cambridge, Massachusetts.